Welcome to BioSeeker Group!

Triple Analysis: Pancreatic Cancer, Cancer Vaccines and Antibodies

Additional Information

Published Date Mar 19, 2013
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 4471
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Pancreatic Cancer, Cancer Vaccines and Antibodies in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Pancreatic Cancer), one mechanism/target/effect area (Cancer Vaccines) and one compound specific area (Antibodies).

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Pancreatic Cancer, Cancer Vaccines and Antibodies.

    To find out more about Triple Analysis: Pancreatic Cancer, Cancer Vaccines and Antibodies, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Pancreatic Cancer, Cancer Vaccines and Antibodies is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Pancreatic Cancer), one mechanism/target/effect area (Cancer Vaccines) and one compound specific area (Antibodies). Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Pancreatic Cancer
The pancreatic cancer report part comprises defined and up to date development strategies for 247 pancreatic cancer drugs within the portfolio of 158 investigators, from Ceased to Marketed. This part extensively analyses their 197 identified drug targets, organized into 163 drug target strategies, and assesses them in eight different compound strategies.
This part is based on the following publication:
Commercializing Pancreatic Cancer Drugs: The Faster Route to Consider Your Options and Position of Others

Part II: Cancer Vaccines
The cancer vaccine drug report part comprises defined and up to date development strategies for 196 drugs in oncology within the portfolio of 114 companies world-wide, from Ceased to Marketed. The report extensively analyses their 137 identified drug targets, organized into 114 drug target strategies, and assesses them in 52 cancer indications.
This part is based on the following publication:
Cancer Vaccines: From First-in-Class to Best-in-Class?

Part III: Antibodies
The antibody drug report part comprises defined and up to date development strategies for 572 drugs in oncology within the portfolio of 205 companies world-wide, from Ceased to Marketed. The report extensively analyses their 270 identified drug targets, organized into 279 drug target strategies, and assesses them in 72 cancer indications.
This part is based on the following publication:
Cancer Antibodies: Drug Target Atlas and Competitive Outlook

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Pancreatic Cancer
5.1 The Scope of this Report 27
6 Consider the Therapeutic Target Among Pancreatic Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (197 Drug Targets) 31-422
7 Emerging New Products to Established Ones: Drug Target Strategies of Pancreatic Cancer Drugs by their Highest Stage of Development (163 Drug Target Strategies and 247 Drugs) 423-612
8 Compound Strategies at Work: Competitive Benchmarking of Pancreatic Cancer Drugs by Compound Strategy (8 Compound Strategies) 613-651
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Pancreatic Cancer Drug Pipeline by Investigator (158 Investigators and 247 Drugs) 652-1088
10 Drug Index 1091
11 Company Index 1098
Figures: Includes 7 Figures
Tables: Includes 218 Tables
Total Number of Pages: 1,103

Part II: Cancer Vaccines
5.1 The Scope of this Report 28
6 Consider the Therapeutic Target Among Cancer Vaccine Drugs for the Highest Therapeutic Outcome and Return on Investment (137 Drug Targets) 32-245
7 First-in-Class and Me-too Analysis of Cancer Vaccine Drugs (114 Drug Target Strategies and 196 Drugs) 246-262
8 Is First-in-Class the Best-in-Class? 263-386
9 Compound Strategies at Work: Competitive Benchmarking of Cancer Vaccine Drugs by Compound Strategy (7 Compound Strategies) 387-413
10 The Competition Through Close Mechanistic Approximation of Cancer Vaccine Drugs 414-416
11 Selecting Indications for Cancer Vaccine Drugs (52 Cancer Indications) 417-492
12 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Vaccine Drug Pipeline by Company (114 Companies and 196 Drugs) 493-993
13 Disclaimer 994
Figures: Includes 5 Figures
Tables: Includes 239 Tables
Total Number of Pages: 1,007

Part III: Antibodies
5.1 The Scope of this Report 35
6 Consider the Therapeutic Target Among Antibody Drugs in Cancer for the Highest Therapeutic Outcome and Return on Investment (270 Drug Targets) 39
7 Emerging Drug Candidates to Established Ones: Drug Target Strategies of Antibody Drugs in Cancer by their Highest Stage of Development (279 Drug Target Strategies and 572 Drugs) 423-776
8 Selecting Indication for Antibody Drugs in Oncology (72 Cancer Indications) 777-907
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Antibody Drug Pipeline by Investigator (205 Investigators and 572 Drugs) 908-2360
10 Disclaimer 2361
Figures: Includes 7 Figures
Tables: Includes 355 Tables
Total Number of Pages: 2,361

This Report Includes the Following Companies:
A&G Pharmaceutical
AB Science
Abbott
Abcam
Abiogen
Ablynx
AC Immune
Acceleron Pharma
Access
Actinium Pharmaceuticals
Active Biotech
Adaptimmune
Adherex
Advantagene
Advaxis
AEgera
Affibody
Affimed Therapeutics
Affitech
Agenus
AGY Therapeutics
Aida Pharmaceuticals
Alder Biopharmaceuticals
Alethia Biotherapeutics
Alexion
Algeta
AlphaVax
ALSP
Altor BioScience
Amgen
Amorfix Life Sciences
Antisense Pharma
Antisoma
Anza Therapeutics
Aphios
Apogee Biotechnology
Apotex
Apricus Biosciences
Arana Therapeutics
Arca biopharma
Ardea Biosciences
Areva
arGEN-X
Argos Therapeutics
Ariad
ArQule
Array BioPharma
Astellas
AstraZeneca
AVEO
AVI BioPharma
Bavarian Nordic
Bayer
Bellicum Pharmaceuticals
Berkeley Lab
Betapharma
Biocon
Biogen Idec
BioInvent
Biolex
BioLineRx
Bionovo
BioNTech
BioNumerik
BioSante
Biosceptre
Biostar
Biotecnol
Biotest
BioVex
Boehringer Ingelheim
BreakThrough Therapeutics
Bristol-Myers Squibb
BTG
Calando Pharmaceuticals
Cancer Advances
Cancer Innovations
Cancer Research Technology
Celera
Celgene
Cell Therapeutics
Celldex Therapeutics
Celltrion
Celsion
Celtic Pharma
Center of Molecular Immunology
Centrose
CG Therapeutics
Circadian Technologies
CompleGen
Cornerstone Pharmaceuticals
Cosmo Pharmaceuticals
CreaGene
CritiTech
CSL
CuraGen
Curaxis
CureTech
CureVac
Curis
Customized Therapeutics
Cyclacel
Cylene Pharmaceuticals
Cynvec
CytImmune Sciences
Cytokinetics
CytRx
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dara Biosciences
Dendreon
DeveloGen
DiaMedica
Dompe
Dr Reddy’s
Dyax
EGEN Inc
Eisai
Elan
Eli Lilly
Emergent BioSolutions
EntreMed
Epeius Biotechnologies
EpiCept
Ergon Pharmaceuticals
Esperance Pharmaceuticals
Etubics
EUSA Pharma
Exelixis
Expression Drug Designs
Fabrus
Faron Pharmaceuticals
Favrille
Femta Pharmaceuticals
FibroGen
Five Prime Therapeutics
Fusion Antibodies
Galaxy Biotech
Galectin Therapeutics
Galena Biopharma
GammaCan
Ganymed Pharmaceuticals
Gene Techno Science
Genencor
Genentech
Generex
Genmab
GenOdyssee Pharmaceuticals
Genomic Systems
GenPat77
Genta
Genticel
GenVec
Geron
Gilead Sciences
GlaxoSmithKline
Gliknik
GlobeImmune
GlycoGenesys
Glycotope
Gradalis
Green Cross
Hawthorn Pharmaceuticals
Heat Biologics
Hemispherx Biopharma
Hoffmann-La Roche
Human Genome Sciences
Ichor Medical Systems
Idera Pharmaceuticals
IDM Pharma
ImClone Systems
IMED
immatics biotechnologies
Immune Pharmaceuticals
ImmunoCellular Therapeutics
ImmunoFrontier
ImmunoGen
Immunomedics
Immunotope
Immunovaccine
ImmuPharma
Immutep
Innate Pharma
InNexus Biotechnology
Innovive
Inovio
Insmed
Insys Therapeutics
Intracel
Introgen Therapeutics
Ipsen
ISA Pharmaceuticals
ISU ABXIS
Jennerex Biotherapeutics
Johnson & Johnson
Kadmon
KAEL-GemVax
Kaketsuken
KaloBios
Kirin Pharma
Kissei
Kyowa Hakko Kirin
Kyto Biopharma
Leo
LFB Biotechnologies
LG Life Sciences
Lipotek
MacroGenics
Mannkind
MAT Biopharma
MBiotec
Meda
Medarex
MediGene
MedImmune
Medisyn Technologies
Menarini
Merck & Co
Merck KGaA
Merrimack
Mersana Therapeutics
MethylGene
Micromet
Mitsubishi Tanabe Pharma
MolMed
Mologen
Momotaro-Gene
Mycenax
Nektar Therapeutics
Nemod Biotherapeutics
Neovacs
Nereus Pharmaceuticals
Neuren
NIH
Nippon Kayaku
Nippon Shinyaku
NKT Therapeutics
Non-industrial source
Northwest Biotherapeutics
Novacea
NovaLead
Novartis
NovaRx
Novogen
OncoMed
OncoMune
OncoTherapy Science
Oncothyreon
Oncovir
Oncozyme Pharma
Onyvax
Orchestra Therapeutics
Oxford BioMedica
OXiGENE
Paladin Labs
Panacea
PanaGin
PanGenetics
Patrys
Pepscan Therapeutics
Peptagen
Peregrine Pharmaceuticals
Perseus Proteomics
Pfizer
PharmAbcine
Pharmacyclics
PharmaForm
PharmaMar
Pharmexa
Philogen
Pierre Fabre
Piramal
Prima Biomed
PROBIOMED
ProCell Therapeutics
Prochon Biotech
Progenics Pharmaceuticals
ProMetic Life Sciences
Protgen
Protherics
Radient Pharmaceuticals
Ramot
Ras Therapeutics
Reata Pharmaceuticals
Recepta biopharma
Receptor BioLogix
Regeneron
Regulon
responsif
RESprotect
Rexahn
Rigel
Rottapharm Madaus
Samyang
Sanofi
Santaris Pharma
Sarepta Therapeutics
SBI Biotech
Scancell
Seattle Genetics
Shanghai CP Guojian
Shenogen
Shionogi
Shire
Stainwei Biotech
Sunol Molecular
SuperGen
SuppreMol
Switch Pharma
Symphogen
Synageva BioPharma
SynerGene Therapeutics
Tactic Pharma
Taiho
Takeda
Talon Therapeutics
Tamir Biotechnology
Tapestry Pharmaceuticals
TapImmune
Targa Therapeutics
Tau Therapeutics
TeGenero
Teva
Thallion Pharmaceuticals
Therion Biologics
ThromboGenics
Titan Pharmaceuticals
Tolerx
TopoTarget
Tracon Pharmaceuticals
Tragara Pharmaceuticals
Transgene
Trillium Therapeutics
Trion Pharma
UCB
UMN Pharma
United Biomedical
United Therapeutics
Vaccinex
Wakunaga
VasGene Therapeutics
Vaxil BioTherapeutics
Vaximm
Vaxon Biotech
VaxOnco
Vectura
Vertex Pharmaceuticals
Vical
Wilex
Vion Pharmaceuticals
VioQuest
Viragen
Virionics
ViroMed
Viventia Biotech
XBiotech
Xencor
Xerion
Xoma
Y’s Therapeutics
Yakult Honsha
YM BioSciences
Zenotech
Zensun
Zeria
Zydus Cadila
A Shortlist of Drugs Included are:
131I-tositumomab
abagovomab
adecatumumab
ADXS11-001
AE-37
AEG-35156
aflibercept
AGS-003
AGS-1C4D4
ALD-518
alemtuzumab
amatuximab
AME-133
AMG-386
ANZ-207
apricoxib
ARC-100
ARQ-197
astuprotimut-r
Auto TAG vaccine
AV-299
AVX-701
bardoxolone methyl
belagenpumatucel-L
belimumab
bevacizumab
BHQ880
blinatumomab
BMS-663513
BMS-936558
bosutinib
BP-GMAX-CD1
brentuximab vedotin
brivanib alaninate
brivudine
BT-062
BV-NSCLC-001
Cabozantinib
capecitabine
carlumab
catumaxomab
CB-10-01
CDX-1307
CDX-1401
celecoxib
cetuximab
CG-201
cilengitide
cixutumumab
CMAB302
CMAB304
conatumumab
CPI-613
CreaVax-PC
CRLX-101
CT-011
CV-9103
CV-9201
CVac
dalotuzumab
daratumumab
dasatinib
DCVax-prostate
denosumab
docetaxel
doxorubicin
E-75
E-7820
elotuzumab
EMD-273063
EMD525797
emepepimut-S
eniluracil
enzastaurin hydrochloride
epratuzumab
epratuzumab-Y90
erlotinib
ertumaxomab
everolimus
farletuzumab
figitumumab
fresolimumab
galiximab
ganitumab
gefitinib
gemtuzumab ozogamicin
GI-4000
girentuximab
glembatumumab vedotin
GS-6634
GSK-1120212
GSK-2130579A
GV-1001
GVAX
GVX-3322
Her-2/Neu peptides
Hi-8 MEL
HS-110
I-131-labetuzumab
ibritumomab tiuxetan
icotinib hydrochloride
icrucumab
ICT-107
imatinib mesilate
imMucin
IMO-2055
IMP-321
inotuzumab ozogamicin
interleukin-12
intetumumab
IPH-2102
ipilimumab
iratumumab
irinotecan
irinotecan hydrochloride
ISA-P53-01
JX-594
KD032
L19-IL2
L19-TNFalpha
lapatinib ditosylate
lestaurtinib
lintuzumab
LIP-131I
LipoVIL12
lorvotuzumab mertansine
lucatumumab
lumiliximab
LY2495655
lymphomun
MABp1
mapatumumab
masitinib
MCS-110
MDX-1379
MEDI-551
MEDI-573
MetXia
MGN-1601
milatuzumab
milatuzumab-doxorubicin
MKC-1
MM-111
MM-121
mocetinostat
mogamulizumab
MOR202
MOR208
MORAb-004
motexafin gadolinium
moxetumomab pasudotox
MVA-BN Her-2 vaccine
nadroparin
naptumomab estafenatox
natalizumab
necitumumab
nimotuzumab
obinutuzumab
oblimersen sodium
ofatumumab
olaparib
olaratumab
onartuzumab
OncoVAX
Onyvax-105
oregovomab
OTS-102
P-276-00
p.DOM-WT1-37/p.DOM-WT1-126 DNA
paclitaxel
PancAtak
panitumumab
panobinostat
pasireotide
pasireotide LAR
PAT-SC1
pazopanib hydrochloride
PCI-27483
pemetrexed disodium
pentamidine isethionate
perifosine
pertuzumab
PF-4856884
plitidepsin
poly-ICLC
polyclonal antibody stimulator
PROSTVAC
PSMA ADC
PX-12
ramucirumab
Reditux
Reximmune-C
Rexin-G
RG-7160
rilotumumab
rindopepimut
rintatolimod
rituximab
robatumumab
romidepsin
romiplostim
RX-0201
S-488410
samalizumab
SAR-3419
SCIB-1
selumetinib
siltuximab
sipuleucel-T
sorafenib tosylate
sotatercept
ß-lapachone
sunitinib malate
Survivac
Sym-004
talminogene laherparepvec
tegafur + uracil
temsirolimus
Tenarad
TG-4010
thymalfasin
tigatuzumab
tipapkinogene sovacivec
tocilizumab
trabedersen
trastuzumab
TRC-105
tremelimumab
triciribine phosphate
TroVax
TRU-016
TS-1
tucotuzumab celmoleukin
U3-1287
Ublituximab
varlitinib
velimogene aliplasmid
veltuzumab
verpasep caltespen
vismodegib
vitespen
volociximab
VX-001
WX-671
yttrium Y 90 clivatuzumab tetraxetan
Z-360
zalutumumab
zanolimumab

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Pancreatic Cancer, Cancer Vaccines and Antibodies.
    To find out more about Triple Analysis: Pancreatic Cancer, Cancer Vaccines and Antibodies, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Pancreatic Cancer, Cancer Vaccines and Antibodies is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Lung Cancer, Melanoma and Antibodies
This triple analysis focuses on cancer drug development strategies in both Lung Cancer and Melanoma and by the compound strategy of Antibodies. Learn More


Triple Analysis: Leukemia, Lymphoma and Antibodies
This triple analysis focuses on cancer drug development strategies in both Leukemia and Lymphoma and by the compound strategy of Antibodies. Learn More

Other selected research from the 'Oncology' category:


Triple Analysis: Colorectal Cancer, Leukemia and Antibodies
This triple analysis focuses on cancer drug development strategies in both Colorectal Cancer and Leukemia and by the compound strategy of Antibodies. Learn More


Protein Kinase Inhibitors Drug Pathway Analyzer
There are today at least 1342 protein kinase inhibitor drugs known to affect more than 251 specific intracellular signaling pathways for the treatment of more than 160 different tumor types. The rational for this plethora of treatment strategies is based on our increasing understanding of the 287 drug targets that are included in this drug-pathway analyzing tool. No less than 280 of these have been recorded with mutations and 57 drug targets have mutations which have been causally implicated in cancer. Learn More